Works by Hooge, Marjolijn N. Lub-de

Results: 6

Advances and challenges in immunoPET methodology.

Published in:

Frontiers in Nuclear Medicine, 2024, p. 1, doi. 10.3389/fnume.2024.1360710

By:

Mohr, Philipp;
van Sluis, Joyce;
Hooge, Marjolijn N. Lub-de;
Lammertsma, Adriaan A.;
Brouwers, Adrienne H.;
Tsoumpas, Charalampos

Publication type:

Article

Advances and challenges in immunoPET methodology.

Published in:

Frontiers in Nuclear Medicine, 2024, p. 1, doi. 10.3389/fnume.2024.1360710

By:

Mohr, Philipp;
van Sluis, Joyce;
Hooge, Marjolijn N. Lub-de;
Lammertsma, Adriaan A.;
Brouwers, Adrienne H.;
Tsoumpas, Charalampos

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.241877

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Hooge, Marjolijn N. Lub-de

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.241877

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Hooge, Marjolijn N. Lub-de

Publication type:

Article

89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922.

Published in:

Journal of Nuclear Medicine, 2010, v. 51, n. 5, p. 761, doi. 10.2967/jnumed.109.071043

By:

Nagengast, Wouter B.;
de Korte, Maarten A.;
Munnink, Thijs H. Oude;
Timmer-Bosscha, Hetty;
den Dunnen, Wifred F.;
Hollema, Harry;
de Jong, Johan R.;
Jensen, Michael R.;
Quadt, Cornelia;
Garcia-Echeverria, Carlos;
van Dongen, Guus A. M. S.;
Hooge, Marjolijn N. Lub-de;
Schröder, Carolien P.;
de Vries, Elisabeth G. E.

Publication type:

Article

89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma.

Published in:

Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-10139-6

By:

Giesen, Danique;
Hooge, Marjolijn N. Lub-de;
Nijland, Marcel;
Heyerdahl, Helen;
Dahle, Jostein;
de Vries, Elisabeth G. E.;
Pool, Martin

Publication type:

Article

Works by Hooge, Marjolijn N. Lub-de

Advances and challenges in immunoPET methodology.

Advances and challenges in immunoPET methodology.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

<sup>89</sup>Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922.

<sup>89</sup>Zr-PET imaging to predict tumor uptake of <sup>177</sup>Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma.